

MassBio Forum—Doing Business With China: Changing Regulatory Reforms and BD Opportunities in China

NOVEMBER 13, 2018
MASSBIO

China is a torrid topic in today's environment for emerging growth life science companies. With large markets and health care opportunities abounding both in China and in the United States, and with opportunities for MA-based life sciences companies to extend their own trajectories, understanding the landscape, horizons and nuances of the Chinese marketplace as well as predilections of Chinese investors and strategic partners, is critically important. This forum will present an overview of the rapidly changing regulatory and market landscape in China. Key topics include:

- Overview of the landscape today and future outlook
- Emergence of innovative Chinese pharmaceutical companies
- Leveraging China to accelerate clinical development path
- Protection of IP in China: Legal concerns and practical solutions
- Impact of regulations on currency, taxes, material import/export, etc.
- Departures from the norm: Joint ventures, strategic partnerships and global licensing

WilmerHale Partner Kenneth Zhou will be a speaker on this panel along with Kate Haviland, CBO of Blueprint Medicines, and Wei Zhao, VP of 6 Dimensions (formerly Wuxi Ventures). Helen Ho, Vice President and Head of Corporate Development at Blueprint Medicines will moderate.

[READ MORE ABOUT THE EVENT](#)

Speakers



Kenneth Zhou

PARTNER

✉ kenneth.zhou@wilmerhale.com

📍 BEIJING ☎ + 86 10 5901 6588

☎ + 1 202 459 8339 (US) 1 391 165 3039 (China)


Related Solutions

Asia
Life Sciences

China Transactions
Technology Transactions and
Licensing

Cross-Border Transactions

You May Be Interested In



AI & Financial Services – Part Two

APRIL 16, 2024

WEBINAR





28th Annual Compliance Institute

APRIL 16, 2024

SPEAKING ENGAGEMENT



A Look Behind the Curtain – Being an Arbitrator or Tribunal Secretary in Turkish and Swiss Arbitrations

APRIL 17, 2024

SPEAKING ENGAGEMENT

[VIEW ALL EVENTS](#)